Translational Sciences, Daiichi Sankyo deal

Translational Sciences granted Daiichi exclusive, worldwide rights to develop and commercialize TS23. Daiichi Sankyo said the blood clot-dissolving antibody is in a Phase I trial. Daiichi will take o...